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simvastatin (35.4%), atorvastatin (27.6%) and pravastatin
(13.2%) were the most prescribed initial drugs. A total of
503,023 patients were considered for the adherence analysis:
34.9% of subjects had MPR < 0.4; 34.7% between 0.4 and 0.8;
and 30.4% > 0.8. CONCLUSION: Persistent and adherence
with hypolipemic medications is far from optimal in this large
cohort of subjects. This phenomenon is common to many asymp-
tomatic chronic therapies and deserves further investigations, as
it indicates that a relevant part of drug resources are spent
without a predictable clinical beneﬁt.
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OBJECTIVES: Combination pharmacotherapy is often necessary
to treat hypertension, but can negatively impact patient compli-
ance. This analysis assesses the impact of combination therapy
with valsartan and amlodipine, with or without hydrochlorthi-
azide (HCTZ), on medication possession ratios (MPR) in a
previously antihypertensive naïve population. METHODS: A
national database of insured hypertensive patients > age 18 pre-
viously antihypertensive naïve was evaluated for combination
pharmacotherapy. Dual therapy with valsartan and amlodipine
was initiated within the ﬁrst 180 days of pharmacotherapy.
Triple therapy with valsartan-amlodipine-HCTZ could occur in
two manners during the ﬁrst 365 days of pharmacotherapy:
combination as three free drug components, or a proprietary
ﬁxed dose combination of valsartan and HCTZ with amlodipine.
All three groups had at least two claims for the combination
during the 365 days following initiation of the combination.
RESULTS: Using hypertension ICD-9 codes (401.0, 401.1,
401.9, 402.1 & 402.9) 908 subjects met study criteria for com-
bination pharmacotherapy: 224 on dual therapy, 63 on free triple
therapy, and 615 on ﬁxed dose triple therapy. MPR values
decreased with the increase in tablets per regimen: dual therapy
0.779, ﬁxed dose triple 0.734, free triple 0.694 (P = 0.0149). A
trend towards improved MPR with increasing age was noted
between cohorts, and in the general population increased from
0.7 in ages 18–35 to 0.77 for subjects > 65 (P = 0.0058) A trend
towards improved MPR with increasing severity of cardiovascu-
lar disease was also noted. MPR values for subjects with the
highest disease burden (>2 comorbid cardiovascular diseases)
followed a similar pattern: dual 0.791, triple ﬁxed 0.745, triple
free 0.654 (P = 0.067). CONCLUSION: Patient compliance
improves with simpliﬁed pharmacotherapy approaches. Dual
therapy provided the best MPR values, followed by triple drug
therapy using two tablets (ﬁxed dose valsartan HCTZ plus amlo-
dipine). Other factors positively inﬂuencing compliance were
advancing age and overall cardiac disease burden.
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OBJECTIVES: The study evaluates adherence with antihyper-
tensive drug treatments in newly treated patients, outlines char-
acteristics of patients discontinuing treatment (discontinuation
risk proﬁling), and calculates amount of resources allocated on
not effective treatment patterns (eg, discontinuation). An admin-
istrative database kept by the Local Health Unit of Pavia listing
patient baseline characteristics, drug prescriptions and hospital
admissions was used to perform a population-based retrospec-
tive analysis. METHODS: The study included all newly treated
users of antihypertensive drugs, 18 years of age, receiving a
ﬁrst prescription for diuretics, beta-blockers, calcium channel-
blockers, ACE inhibitors, angiotensin II antagonists or other
antihypertensive drugs between January 1st, 2001 and Decem-
ber 31st, 2003. Patients were observed for 365 days. Adherent
patients were deﬁned as having a duration of therapy >273 days
and DDD-standardized mean daily dose 0.8. RESULTS: A
total of 42,000 patients were included in the study.Excluding
ACE inhibitors (34.3%) other antihipertensive classes were
included in a range from 13.3% up to 18.8%. The 75.1% of
patients was not adherent to antihypertensive treatment. Those
prescribed with angiotensin II antagonists were more likely to
adhere treatment than those started on other antihypertensive
classes. Poor adherence was associated with younger age, lower
prevalence of concurrent chronic pharmacotherapies and lower
prevalence of previous hospitalizations for cardiovascular dis-
eases. The overall cost amounted to € 5.320 mio € of which
36.4% was accounted for not adherent patients. CONCLU-
SION: The clinical, social, and economic importance of treating
hypertension requires the analysis and the implementation of
tools for monitoring antihypertensive drug utilization as to
assess the extent to which results from clinical research are
brought into clinical practice. Administrative databases offer a
powerful and low cost tool, providing detailed and useful,
population-wide epidemiological and economic information for
antihypertensive drug utilization.
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